TG101209

TG101209 is a potent, small-molecule selective inhibitor of **Janus kinase 2 (JAK2)**, specifically designed using structure-based drug design to target the **JAK2V617F** mutation. This mutation is a hallmark of various myeloproliferative neoplasms (MPNs), including primary myelofibrosis and polycythemia vera. TG101209 also demonstrates inhibitory activity against other tyrosine kinases, such as **FLT3** and **RET**. Its mechanism of action involves the suppression of the JAK-STAT signaling pathway, which leads to the down-regulation of pro-survival proteins like Bcl-2, induction of cell cycle arrest at the G2/M phase, and the triggering of apoptosis and autophagy. Preclinical research has highlighted its potential efficacy in treating **T-cell acute lymphoblastic leukaemia (T-ALL)**, **multiple myeloma**, and **lung cancer**.